Pharmacokinetic and dose‐finding study of osimertinib in patients with impaired renal function and low body weight

The safety of osimertinib is limited in patients with severe or moderate renal impairment, or low body weight. This study aimed to investigate the safety, pharmacokinetics (PK) and recommended dose (RD) of osimertinib in patients with epidermal growth factor receptor (EGFR)‐mutated non–small cell lu...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujiwara, Yutaka, Makihara, Reiko, Hase, Tetsunari, Hashimoto, Naozumi, Naito, Tomoyuki, Tsubata, Yukari, Okuno, Takae, Takahashi, Toshiaki, Kobayashi, Haruki, Shinno, Yuki, Zenke, Yoshitaka, Ikeda, Takaya, Hosomi, Yukio, Watanabe, Kageaki, Kitazono, Satoru, Sakiyama, Naomi, Makino, Yoshinori, Yamamoto, Noboru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10154887/
https://www.ncbi.nlm.nih.gov/pubmed/36704833
http://dx.doi.org/10.1111/cas.15736

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10154887/
https://www.ncbi.nlm.nih.gov/pubmed/36704833
http://dx.doi.org/10.1111/cas.15736

Ejemplares similares